Literature DB >> 25846194

Clinical, structural, biochemical and X-ray crystallographic correlates of pathogenicity for variants in the C-propeptide region of the COL3A1 gene.

Natasha S Stembridge1, Anthony M Vandersteen2, Neeti Ghali1, Philip Sawle1, Mandy Nesbitt3, Rebecca C Pollitt3, David J P Ferguson4, Simon Holden5, Frances Elmslie6, Alex Henderson7, David J S Hulmes8, F Michael Pope1.   

Abstract

Vascular Ehlers-Danlos syndrome (vEDS) is a heritable disorder of connective tissue caused by pathological variants in the COL3A1 gene, which encodes the α1 chain of type III collagen. Type III collagen is a major component of skin, arterial walls, and the gastrointestinal tract. Collagen III protein deficiency manifests as an increased risk of rupture, perforation, and dissection of these structures. The most disruptive gene variants affect the collagen helix via glycine substitutions or splice donor site mutations. The C-propeptide region of COL3A1 includes exons 49-52 and has a crucial role in initiating the C-terminal assembly of procollagen monomers in the early stages of collagen biosynthesis. Nineteen COL3A1 variants have previously been reported in these exons, of which four were associated with a severe vEDS phenotype. We identified two novel C-propeptide missense variants; p.Pro1440Leu, p.Arg1432Leu, and a non-stop mutation, c.4400A > T, p. (*1467Leuext*45). These variants produce variable phenotypes ranging from obvious acrogeria to classical or hypermobile EDS. A previously reported variant p.Lys1313Arg is of unknown clinical significance but likely benign, based on this study. Assigning disease pathogenicity remains complex, clinical phenotyping and crystal structure evidence being crucial. We briefly compare reported phenotypes for patients with missense variants in the C-propeptide domain for other human collagen disorders including COL1A1 and COL1A2 (osteogenesis imperfecta).
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  C-propeptide domain; X-ray crystallography; type III procollagen gene [COL3A1]; vascular Ehlers-Danlos syndrome [type IV]

Mesh:

Substances:

Year:  2015        PMID: 25846194     DOI: 10.1002/ajmg.a.37081

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  5 in total

Review 1.  Type III collagen (COL3A1): Gene and protein structure, tissue distribution, and associated diseases.

Authors:  Helena Kuivaniemi; Gerard Tromp
Journal:  Gene       Date:  2019-05-07       Impact factor: 3.688

2.  The collαgen III fibril has a "flexi-rod" structure of flexible sequences interspersed with rigid bioactive domains including two with hemostatic roles.

Authors:  J Des Parkin; James D San Antonio; Anton V Persikov; Hayat Dagher; Raymond Dalgleish; Shane T Jensen; Xavier Jeunemaitre; Judy Savige
Journal:  PLoS One       Date:  2017-07-13       Impact factor: 3.240

Review 3.  Molecular Basis of Pathogenic Variants in the Fibrillar Collagens.

Authors:  Allan J Richards; Martin P Snead
Journal:  Genes (Basel)       Date:  2022-07-04       Impact factor: 4.141

4.  Targeted next-generation sequencing makes new molecular diagnoses and expands genotype-phenotype relationship in Ehlers-Danlos syndrome.

Authors:  Ruwan A Weerakkody; Jana Vandrovcova; Christina Kanonidou; Michael Mueller; Piyush Gampawar; Yousef Ibrahim; Penny Norsworthy; Jennifer Biggs; Abdulshakur Abdullah; David Ross; Holly A Black; David Ferguson; Nicholas J Cheshire; Hanadi Kazkaz; Rodney Grahame; Neeti Ghali; Anthony Vandersteen; F Michael Pope; Timothy J Aitman
Journal:  Genet Med       Date:  2016-03-24       Impact factor: 8.822

5.  A novel mutation in COL3A1 associates to vascular Ehlers-Danlos syndrome with predominant musculoskeletal involvement.

Authors:  Federica Ruscitti; Lucia Trevisan; Giulia Rosti; Fabio Gotta; Annalia Cianflone; Alessandro Geroldi; Paola Origone; Anna Pichiecchio; Simona Viglio; Maria Iascone; Paola Mandich
Journal:  Mol Genet Genomic Med       Date:  2021-07-28       Impact factor: 2.183

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.